Regenerative Medicine / Clinical-Stage Biotechnology
Strategic Profile
The company is focused on top-line Phase 2b HLHS results expected in Q3 2026; FDA guidance indicated a successful trial could serve as a pivotal study for a BLA. The company has obtained regulatory designations including Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT). Longeveron appointed Stephen H. Willard as CEO, effective February 11, 2026, replacing interim CEO Than Powell.
Cyborg Score Rationale
The company received a Nasdaq notice in September 2025 that its stock had fallen below the $1.00 minimum bid price requirement, initiating a compliance period for continued listing. While there are significant advancements in clinical trials and a robust pipeline with favorable FDA designations, the company faces financial challenges, including declining revenues, increased expenses, and potential delays in regulatory filings.
Top Insights
Phase 2b ELPIS II trial for HLHS enrolled 40 pediatric patients at 12 centers with top-line results anticipated in Q3 2026, representing the most critical near-term catalyst for the company.
U.S. Patent No. 12,496,316 granted December 17, 2025 for methods of administering isolated allogeneic mesenchymal stem cells to treat female sexual dysfunction, expanding the therapeutic portfolio beyond cardiovascular and neurological indications.
2024 revenue increased 237.38% to $2.39 million, but net losses were -$24.62 million, 10.9% more than in 2023, indicating pre-commercial cash burn challenges.
Two analysts rate the stock "Strong Buy" with a 12-month price target of $6.5, implying 1,030% upside potential from current valuations.
Named Competitors
Autologous Stem Cell Therapies — Autologous MSC-based approaches for regenerative medicine applications
Allogeneic Cell Therapies — Off-the-shelf allogeneic stem cell products competing for same indications
Exosome and Secretome Therapeutics — Alternative regenerative medicine platforms targeting aging and cardiovascular disease
Recent Developments
(February 2026) Stephen H. Willard appointed CEO effective February 11, 2026
(December 2025) U.S. Patent granted for female sexual dysfunction indication (Patent No. 12,496,316)
(January 2026) Selected as StartUp Health Alzheimer's & Brain Health Moonshot company for JPM Healthcare Week participation
Open the full interactive Longeveron Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.